Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
41 hedge funds and large institutions have $181M invested in Adaptimmune Therapeutics in 2015 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less funds holding
Funds holding: 45 → 41 (-4)
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
52% less capital invested
Capital invested by funds: $380M → $181M (-$198M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$8.76M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$6.76M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$3.59M |
| 4 |
Jennison Associates
New York
|
+$1.91M |
| 5 |
IHM
Iguana Healthcare Management
New York
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$59.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$19M |
| 3 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
-$8.78M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$4.94M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$4.58M |
ADAP Hedge Fund Activity: Q3 2015 in Review
41 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2015, worth a combined $181M — down 52% from $380M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ADAP and 6 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 9 added.
The largest buyer was Capital World Investors, adding an estimated $8.76M. The largest seller was OrbiMed, cutting an estimated $59.8M.
- 41 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2015, down from 45 in Q2 2015.
- Funds reported $181M of Adaptimmune Therapeutics stock for Q3 2015, down 52% quarter-over-quarter.
- 6 funds opened new Adaptimmune Therapeutics positions in Q3 2015 and 10 closed out, a net change of -4 holders.
- The largest Adaptimmune Therapeutics buyer in Q3 2015 was Capital World Investors, an estimated $8.76M added.
- The largest Adaptimmune Therapeutics seller in Q3 2015 was OrbiMed, an estimated $59.8M sold.
Based on aggregated 13F filings for Q3 2015.